02

Application Number: 10/821,382

RECEIVED CENTRAL FAX CENTER

SEP 2 7 2006

Amendments on the original claims

What is claimed is:

1. (currently amended) A phenylaminopyrimidine derivative compound of formula (I)

$$R_1$$
 R_2
 R_3
 R_4

Formula (I)

Wherein

X is oxygen or sulfur,

Y is a direct bond, oxygen, nitrogen or lower alkyl,

Z is an aliphatic, cycloaliphatic, aryl or a heterocyclyl radical,

R₁ is heterocyclyl radical,

R2 is hydrogen, halogen, halogenlower alkyl, lower alkyl or lower alkoxyl,

R₃ is hydrogen or lower alkyl,

R₄ is oxy-lower alkylamino, lower alkyl oxy-lower alkylamino, oxyheterocyclyl, lower alkyl oxyheterocyclyl, oxy-lower alkylheterocyclyl, lower alkyl oxy-lower alkylheterocyclyl, halogenlower alkylamino, halogenlower alkylamino, lower alkylamino, lower alkylamino,

aminoheterocyclyl with the proviso that heterocyclyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alkypiperidinyl,

lower alkylamino heterocyclyl with the proviso that lower alkyamino defined herein is not para-substituted with -CH₂NH- when Z is the phenyl ring.

amino lower alkylheterocyclyl or lower alkylamino lower alkylheterocyclyl, or a pharmaceutically acceptable salt thereof.

(currently amended) A compound of Formula (I) according to claim 1, wherein
X is oxygen or sulfur,

Y is a direct bond, oxygen, nitrogen or lower alkyl,

Z is an aliphatic, cycloaliphatic, aryl or a heterocyclyl radical,

R₁ is heterocyclyl radical,

R2 is hydrogen, halogen, halogenlower alkyl, lower alkyl or lower alkoxyl,

R₃ is hydrogen or lower alkyl,

R4 is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl aminopyridinyl, oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl pyrrolidinyl, lower alkyl oxy-lower alkyl piperidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl pyrrolidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl aminopyridinyl,
- (d) amino lower alkyl unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl aminopyridinyl,

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alkylpyrrolidinyl,

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkylamino lower alkylamino lower alkylamino lower alkylaminopyridinyl,

lower alkylamino heterocyclyl with the proviso that lower alkylamino defined herein is not para-substituted with -CH₂NH- when Z is the phenyl ring.

or a pharmaceutically acceptable salt thereof.

3. (currently amended) A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond,

Z is an aliphatic, cycloaliphatic, aryl or a heterocyclyl radical,

R₁ is heterocyclyl radical,

R2 is hydrogen, halogen, halogenlower alkyl, lower alkyl or lower alkoxyl,

R₃ is hydrogen or lower alkyl,

R4 is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl aminopyridinyl, oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl piperidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl aminopyridinyl, lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl aminopyridinyl,
- (d) amino lower alkyl unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl piperazinyl, amino lower alkyl aminopyridinyl,

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alkylpyrrolidinyl,

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl pyrrolidinyl, lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkyl aminopyridinyl,

lower alkylamino heterocyclyl with the proviso that lower alkylamino defined herein is not para-substituted with -CH₂NH- when Z is the phenyl ring,

or a pharmaceutically acceptable salt thereof.

4. (currently amended) A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond,

Z is aryl,

R₁ is heterocyclyl radical,

R2 is hydrogen, halogen, halogenlower alkyl, lower alkyl or lower alkoxyl,

R₃ is hydrogen or lower alkyl,

R4 is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl aminopyridinyl, oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl pyrrolidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl aminopyridinyl, lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl pyrrolidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl aminopyridinyl,
- (d) amino lower alkyl unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl piperazinyl, amino lower alkyl aminopyridinyl,

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alky piperidinyl.

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino;
 lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl pyrrolidinyl,

lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkyl aminopyridinyl,

lower alkylamino heterocyclyl with the proviso that lower alkylamino defined herein is not para-substituted with -CH₂NH- when Z is the phenyl ring.

or a pharmaceutically acceptable salt thereof.

5. (currently amended) A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond,

Z is aryl,

R₁ is heterocyclyl radical,

R₂ is halogenlower alkyl or lower alkyl,

R₃ is hydrogen or lower alkyl,

R4 is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl aminopyridinyl, oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl pytrolidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl oxy-pytrolidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono-or difluoro substituted lower alkyl piperazinyl, mono-or difluoro substituted lower alkyl aminopyridinyl,
- (d) amino lower alkyl unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl piperazinyl, amino lower alkyl aminopyridinyl,

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alky piperidinyl.

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkylaminopyridinyl,

lower alkylamino heterocyclyl with the proviso that Iower alkyamino defined herein is not para-substituted with -CH₂NH- when Z is the phenyl ring.

or a pharmaceutically acceptable salt thereof.

6. (currently amended) A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond,

Z is aryl,

R₁ is heterocyclyl radical,

R₂ is lower alkyl,

R₃ is hydrogen,

R₄ is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl-aminopyridinyl, oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl piperidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl oxy-piperidinyl, lower alkyl oxy-piperidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl aminopyridinyl,
- (d) amino lower alkyl unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperazinyl, amino lower alkyl aminopyridinyl,

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpytrolidinyl or N-lower alky piperidinyl,

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkylamino lower alkylaminopyridinyl,

lower alkylamino heterocyclyl with the proviso that lower alkyamino defined herein is not para-substituted with -CH₂NH- when Z is the phenyl ring.

or a pharmaceutically acceptable salt thereof.

7. (currently amended) A compound of Formula (I) according to claim 1, wherein

X is oxygen,

Y is a direct bond,

Z is phenyl,

R₁ is: 3-pyridyl or 4-pyridyl

R2 is: methyl, F, Cl or hydrogen,

R₃ is hydrogen,

6266080397

6266080397


R₄ is (cont'd):

- R is hydrogen, lower alkyl, aliphatic, or cycloaliphatic or heterocyclyl radicals, or a pharmaceutically acceptable salt thereof.
- 8. (currently amended) A compound of Formula (I) according to claim 1 is selected from:
- [4-(2-aminoethoxy)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)-pyrimidin-2-
- yl)amino]phenyl}carboxamide
- N {4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl} {4-[(1-methylpyrrolidin-3-yl)amino]phenyl} carboxamide
- [4-(fluoropiperazinylmethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)-pyrimidin-2-
- yl)amino]phenyl}carboxamide
- N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}-{4-[(1-methylpyrrolidin-2-yl)amino]phenyl}-{4-[(1-met
- yl)methoxy]phenyl}carboxamide
- N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}[4-(pyrrolidin-3-
- ylamino)phenyl]carboxamide
- [4-(aminofluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-
- yl)amino]phenyl}carboxamide
- N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}[4-(methylpyrrolidin-3-ylamino)phenyl]carboxamide
- 2-yl)amino]phenyl}carboxamide
- [4-(aminodifluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-
- yl)amino]phcnyl}carboxamide
- {4 [methyl(1-mothylpyrrolidin 3-yl)amino]phenyl} N {4-methyl-3 [(4 (3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
- pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
- {4-[fluoro(methylpyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-
- pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
- [4-({[2-(dimethylamino)ethyl]amino}fluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

(difluoropiperazinylmethyl)phenyl]-N-(4-mothyl-3-[(4-(3-pyridyl)pyrimidin-2-

`{[2-(dimethylamino)ethyl]amino}dilluoromethyl)phenyl]-N-(4-methyl-3-[(4-(3-dyl)pyrimidin-2-yl)amino]phenyl) carboxamide fluoro[methyl(1-methylpyrrolldin-3-yl)amino]methyl}-phenyl)-N-(4-methyl-3-[(4-yridyl)pyrimidin-2-yl)amino]phenyl}-aarboxamide fluoro(pyrrolldin-3-ylamino)methyl]phenyl}-N-(4-methyl-3-[(4-(3-yl)uvrimidin-2-yl)amino]nhenyl}-carboxamide

(4-[difluoro(methylpyrrolidin-3-ylamino)methyl]phonyl)-N-(4-methyl-3-[(4-(3-



methanesultoric acid sail.

10. (oursently amended) A pharmaceutical composition eestaining which comprises as at active incredient a compound of formula (f) according to an defined in any one of claims 1 to 9 g or a pharmaceutical acceptable sail thereof of the compound of the compound and together with a pharmaceutical acceptable carrier.

Respectfully submitted. GUOQING PAUL CHEN Tel: 626-482-9676 Dated: September 27, 2006